<DOC>
	<DOCNO>NCT00162435</DOCNO>
	<brief_summary>The response warfarin varies greatly among individual . Some variability ascribe genetic polymorphism gene encode CYP2C9 , enzyme mediate metabolism S warfarin . In addition genetic polymorphism gene ( i.e . VKORC1 , factor VII ) show account variability response warfarin irrespective CYP2C9.The present study several segment : 1 . Evaluation relationship genetic polymorphism gene encode CYP2C9 , VKORC1 factor VII warfarin maintenance dose steady state . This study confirmation previous data population . 2 . Evaluation relationship genetic polymorphism gene encode CYP2C9 , VKORC1 factor VII warfarin load dose induction period . 3 . Testing hypothesis warfarin load base individual 's combined CYP2C9 , VKORC1 factor VII genotype may efficient associate reduced adverse drug effect .</brief_summary>
	<brief_title>Genetic Determinants Warfarin Anticoagulation Effect</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Patients warfarin initiate Desired therapeutic range &gt; 2 &lt; 3 Refusal participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>